India and drug #patents : The Ghost of #Glivec haunts #Sovaldi

Dr Kristina LybeckerApothecurry welcomes back guest columnist Dr Kristina Lybecker. Her latest column is an elegantly simple “where the rubber hits the road” exposition of the recent rejection of patents on US biopharma company Gilead’s Hepatitis C drug Sovaldi in India. Coincidentally, Gilead’s European patent on Sovaldi was challenged yesterday by charity Medicins du Monde marking yet another interesting turn of events in this breakthrough drug’s eventful life. Read on as Dr Lybecker explains how the Indian Patent Office’s decision rather than aiding clarity in the understanding of India’s patent rules has only muddied the waters. Continue reading “India and drug #patents : The Ghost of #Glivec haunts #Sovaldi”

India’s compulsory licence to Natco : First cut

I quickly read through the Indian Patent Office’s order granting a compulsory licence to Hyderabad’s Natco to make and sell its generic of Bayer’s patented liver and kidney cancer drug Nexavar in India.  While I’m no legal expert and I’ve just speed-read the order, some things just stand out so here goes. Continue reading “India’s compulsory licence to Natco : First cut”